442 IMMUNOREACT 3: PERITUMORAL IMMUNE MICROENVIRONMENT MARKERS AS PREDICTORS OF RECURRENCE AFTER ADJUVANT THERAPY IN LOCALLY ADVANCED RECTAL CANCER
Francesca Bergamo(Istituto Oncologico Veneto), Marco Scarpa(University of Padua), Roberta Salmaso, Giulia Noaro(AULSS 2 Marca Trevigiana), Monica Ortenzi(Marche Polytechnic University), Giulia Becherucci(University of Padua), Riccardo Cerantola, Alessandra Anna Prete, Salvatore Pucciarelli(Azienda Ospedale - Università Padova), Ignazio Castagliuolo(University of Padua), Maurizio Zizzo(Azienda Sanitaria Unità Locale di Reggio Emilia), Giulio Leo(University of Modena and Reggio Emilia), Ivana Cataldo(Ospedale SS. Annunziata), Giuseppe Portale(University of Southern California), Giulia Pozza(University of Padua), Daunia Verdi(ASL Roma), Cesare Ruffolo(Ca' Foncello Hospital), Astghik Stepanyan(University of Padua), Marco Massani(AULSS 2 Marca Trevigiana), Silvia Negro(University of Padua), Stefano Brignola(University of Padua), Roberto Merenda(Ospedale Civile di Venezia), Tommaso Stecca(Ca' Foncello Hospital), Giorgio Rivella(University of Padua), Antonio Scapinello(Istituto Oncologico Veneto), Matteo Fassan(University of Padua), Romeo Bardini(University of Padua), Pierluigi Pilati(Istituto Oncologico Veneto), Francesco Cavallin, Marco Agostini(University of Padua), Licia Laurino(University of Padua), Gianluca Businello(University of Padua), Luca Saadeh(University of Padua), Gaya Spolverato(University of Padua), Andromachi Kotsafti(Istituto Oncologico Veneto), Carlotta Ceccon(University of Padua), Ottavia De Simoni(Istituto Oncologico Veneto), Isabella Mondi(Ospedale di Mirano), Giovanni Pirozzolo(Ottawa Hospital), Barbara Di Camillo(University of Padua), Alfonso Recordare(Ca' Foncello Hospital), Imerio Angriman, Boris Franzato(Istituto Oncologico Veneto), Giovanni Bordignon(AULSS 2 Marca Trevigiana), Chiara Vignotto(University of Padua), Anna Pozza(University of Padua), Giulia Casale, Andrea Porzionato(University of Padua), Valerio Pellegrini(University of Padua), Silvio Guerriero
Cited by 0
Related Papers
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709